You have 1 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AKR1B10

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Combination of AKR1B10 and CA19-9 Improves Diagnosis of PDAC

Recruiting
  • Pancreatic Ductal Adenocarcinoma
    • Shanghai, Shanghai, China
    • +2 more
    Jul 13, 2022

    Healthy Trial in Pretoria (H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose)

    Not yet recruiting
    • Healthy
    • H107e
    • +10 more
    • Pretoria, Gauteng, South Africa
      Aurum Institute
    Sep 24, 2023

    EBV-positive Nasopharyngeal Carcinoma Trial in Guangzhou (Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg,

    Not yet recruiting
    • EBV-positive Nasopharyngeal Carcinoma
    • Cohort A: 3.0x10^6 CAR-T cells/kg
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 16, 2023

    DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • High-grade B-cell Lymphoma
    • Loncastuximab Tesirine
    • (no location specified)
    Dec 13, 2022

    Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

    Completed
    Has Results
    • Lymphoma, Non-Hodgkin
    • +3 more
    • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
    • +3 more
    • Milwaukee, Wisconsin
      Froedtert Hospital & Medical College of Wisconsin
    Jun 26, 2022

    B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

    Recruiting
    • B-cell Non Hodgkin Lymphoma
    • B-cell Chronic Lymphocytic Leukemia
    • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
    • +3 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin and Froedtert Hospital
    Jul 1, 2022

    CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level

    Recruiting
    • CAR
    • +2 more
    • ThisCART19A with Dose Level 1
    • ThisCART19A with Dose Level 2
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jan 18, 2023

    Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

    Recruiting
    • Non-Malignant Neoplasm
    • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 29, 2022

    Cytokine Release Syndrome Trial (CTO1681 10 µg, CTO1681 20 µg, CTO1681 30 µg)

    Not yet recruiting
    • Cytokine Release Syndrome
    • CTO1681 10 μg
    • +2 more
    • (no location specified)
    Jun 6, 2023

    Krabbe Disease Trial in Ann Arbor (FBX-101)

    Recruiting
    • Krabbe Disease
    • FBX-101
    • Ann Arbor, Michigan
      University of Michigan Hospitals - Michigan Medicine
    Feb 13, 2023

    HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

    Not yet recruiting
    • HIV-1-infection
    • Mbeya, Tanzania
      National Institute for Medical Research-Mbeya Medical Resarch Ce
    Jun 6, 2023

    Type 1 Diabetes Trial in La Jolla (Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo)

    Completed
    • Type 1 Diabetes
    • Dapagliflozin 10 MG [Farxiga]
    • +2 more
    • La Jolla, California
      UC San Diego Altman Clinical & Translational Research Institute
    Jan 20, 2023

    Diabetes, Type 2 Trial in Seoul (BR3003(T), BR3003B(R1), BR3003C(R2))

    Completed
    • Diabetes Mellitus, Type 2
    • Seoul, Gwanakgu, Korea, Republic of
      Clinical Research Center, H PLUS Yangji Hospital
    Jul 25, 2022

    HIV-1-infection, Subtype b Trial (Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2)

    Recruiting
    • HIV-1-infection, Subtype b
    • Decitabine cycle 1
    • +7 more
    • Bruxelles, Belgium
    • +2 more
    Jan 30, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
    • +4 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Sep 22, 2022

    COVID-19 Trial (Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5)

    Not yet recruiting
    • COVID-19
    • Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
    • +3 more
    • (no location specified)
    Dec 22, 2022

    Hematologic Diseases Trial in Palo Alto (biological, device, drug)

    Recruiting
    • Hematologic Diseases
    • Allogeneic Stem Cell Transplant
    • +2 more
    • Palo Alto, California
      Lucile Packard Children's Hospital
    Mar 25, 2022

    Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +13 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Aug 18, 2022

    Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

    Active, not recruiting
    • Ann Arbor Stage I Grade 1 Follicular Lymphoma
    • +3 more
    • Clinical Observation
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

    Recruiting
    • B Acute Lymphoblastic Leukemia
    • +2 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Dec 16, 2022

    Gonorrhea Trial in Prague (Cefixime, Doxycyclin, Ceftriaxon)

    Completed
    • Gonorrhea
    • Prague, Czechia
    • +1 more
    Oct 19, 2023

    Mantle Cell Lymphoma Trial in United States (Acalabrutinib, Bortezomib, Cyclophosphamide)

    Recruiting
    • Mantle Cell Lymphoma
    • New Orleans, Louisiana
    • +5 more
    Dec 13, 2022

    Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +3 more
    • Laboratory Biomarker Analysis
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 26, 2022

    Diabetes, Type 1 Trial in Oxford (Dapagliflozin 10 MG Oral Tablet)

    Terminated
    • Diabetes Mellitus, Type 1
    • Dapagliflozin 10 MG Oral Tablet
    • Oxford, Oxfordshire, United Kingdom
      Clinical Research Unit, OCDEM, Churchill Hospital
    May 17, 2022